Articles tagged with “antibody-drug-conjugates”

Gilead-Tubulis $5B Acquisition: ADC Oncology Strategy

Analyze Gilead's $5 billion acquisition of Tubulis, examining antibody-drug conjugate (ADC) oncology strategy, market trends, and new clinical platforms.

40 min read

4/17/2026

antibody-drug conjugates gilead sciences tubulis oncology strategy pharma acquisitions targeted cancer therapy adc market trends